Table Evidence profile table for population one No. of studies and study Other Outcome (units, follow-up) design Risk of bias Inconsistency Indirectness Imprecision considerations Results Quality Importance MTA Median OS observational serious 2 not serious not serious serious 5 none Han et al (2015): 1.9 months (95%CI CRITICAL ⨁⨀⨀⨀ studies (k = 2) 38.8–49.9), Yang et al (2014): 41.9 Follow up: range 22.5 months VERY LOW months (95%CI 38.8–49.9) 4 to 30 months; assessed with: Kaplan-Meier estimate (95%CI)1 Median cancer-specific OS observational serious 2 not serious not serious serious 5 none Han et al (2015): 1.9 months (95%CI CRITICAL ⨁⨀⨀⨀ studies (k = 2) 38.8–49.9), Yang et al (2014): 41.9 Follow up: range 22.5 months VERY LOW months (95%CI 38.8–49.9) 4 to 30.0 months; assessed with: Kaplan-Meier estimate (95%CI) Survival rates at 1-,2-,3- and 4 observational serious 2 not serious not serious very serious 6 none Han et al (2015): 1-year: 91.7%, 2-year: CRITICAL ⨁⨀⨀⨀ or 5-years studies (k = 2) 76.5%, 3-year: 47.9% and 4-year: VERY LOW 47.9% Han et al (2015) cancer-specific: Follow up: range 22.5 months cancer-specific survival rate was 1-year: to 30 months; assessed with: 94.7%, 2-year: 73.9%, 3-year: 64.7% Kaplan-Meier estimate (95% CI and 4-year: 64.7%; Yang et al (2015): not reported) 1-year: 89%, 2-year 63%, 3-year 43%, and 5-year: 16% 4 RFA
Table Evidence profile table for population one Outcome (units, follow-up) No. of studies and study design Risk of bias Inconsistency Indirectness Imprecision Other considerations Results Quality Importance MTA Median OS Follow up: range 22.5 months to 30 months; assessed with: Kaplan-Meier estimate (95%CI)1 observational studies (k = 2) serious 2 not serious not serious serious 5 none Han et al (2015): 1.9 months (95%CI 38.8–49.9), Yang et al (2014): 41.9 months (95%CI 38.8–49.9) 4 ⨁⨀⨀⨀ VERY LOW CRITICAL Median cancer-specific OS Follow up: range 22.5 months to 30.0 months; assessed with: Kaplan-Meier estimate (95%CI) observational studies (k = 2) serious 2 not serious not serious serious 5 none Han et al (2015): 1.9 months (95%CI 38.8–49.9), Yang et al (2014): 41.9 months (95%CI 38.8–49.9) 4 ⨁⨀⨀⨀ VERY LOW CRITICAL Survival rates at 1-,2-,3- and 4 or 5-years Follow up: range 22.5 months to 30 months; assessed with: Kaplan-Meier estimate (95% CI not reported) observational studies (k = 2) serious 2 not serious not serious very serious 6 none Han et al (2015): 1-year: 91.7%, 2-year: 76.5%, 3-year: 47.9% and 4-year: 47.9% Han et al (2015) cancer-specific: cancer-specific survival rate was 1-year: 94.7%, 2-year: 73.9%, 3-year: 64.7% and 4-year: 64.7%; Yang et al (2015): 1-year: 89%, 2-year 63%, 3-year 43%, and 5-year: 16% 4 ⨁⨀⨀⨀ VERY LOW CRITICAL RFA
1403%20-%20Final%20Contracted%20Assessment%20Report%20(ACCESSIBLE).docx